Last close · 16 Oct 2026
Rs 31.99 +0.22%
Financials
Liven Pharma Limited (LIVEN) financials
11 years of annual results (FY2016 – FY2026), 28 quarters.
Liven Pharma Limited (LIVEN) reported revenue of Rs 105.8 mn for FY2026 (Jul 2025 – Jun 2026), down 16.9% from FY2025.
It made a loss of Rs 31.1 mn attributable to shareholders (EPS Rs -0.28), a net margin of -29.4%.
No cash dividend was declared for FY2026.
The balance sheet showed net cash of Rs 148.1 mn.
Return on equity was -3.8%.
At Rs 31.99 (close on 16 Oct 2026) the shares trade at 3.67× book value.
Fundamentals
LIVEN at a glance
Revenue · FY2026
Rs 105.8 mn
▼ 16.9% year on year
Profit attributable to shareholders · FY2026
-Rs 31.1 mn
EPS – basic (Rs) · FY2026
Rs -0.28
Dividend per share (Rs) · FY2026
Rs 0.00
Net margin · FY2026
-29.4%
+429.8 pts year on year
Debt to equity · FY2026
3.4%
-2.1 pts year on year
Financial statements
Income statement
Revenue, costs, profit and earnings per share.
- Revenue · FY2026
- Rs 105.8 mn
- Profit attributable · FY2026
- -Rs 31.1 mn
Balance sheet
Assets, liabilities, debt and shareholders' equity.
- Total assets · FY2026
- Rs 1.2 bn
- Equity · FY2026
- Rs 985.5 mn
Financial highlights
LIVEN financial results
| Rs mn | FY2026 Jul 2025 – Jun 2026 | FY2025 * Jul 2024 – Jun 2025 | FY2024 * Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 |
|---|---|---|---|---|---|
| Revenue | 105.8 | 127.3 | 0.0 | 0.0 | 0.0 |
| Gross profit | 26.6 | 18.0 | 0.0 | 0.0 | 0.0 |
| Operating profit | (62.4) | (489.8) | (13.8) | (15.2) | (17.5) |
| Profit after tax | (31.1) | (584.5) | (11.2) | (12.3) | (14.3) |
| Profit attributable to shareholders | (31.1) | (584.5) | (11.2) | (12.3) | (14.3) |
| EPS – basic (Rs) Rs | (0.28) | (7.11) | (0.78) | (0.86) | (1.00) |
| Dividend per share (Rs) Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total assets | 1,216.0 | 822.9 | 119.7 | 131.5 | 144.6 |
| Total equity | 985.5 | 633.9 | (133.8) | (122.6) | (110.3) |
| Total debt | 33.4 | 34.7 | 238.5 | 237.6 | 235.4 |
| Net cash from operating activities | 9.0 | (1.7) | (0.9) | (2.3) | (2.3) |
| Capital expenditure | (29.7) | (32.8) | — | — | — |
| Free cash flow (operating cash flow − capex) | (20.7) | (34.6) | — | — | — |
| Rs mn | TTM to Jun 2026 | Q4 FY2026 Apr – Jun 2026 | Q3 FY2026 Jan – Mar 2026 | Q2 FY2026 Oct – Dec 2025 | Q1 FY2026 Jul – Sep 2025 | Q4 FY2025 Apr – Jun 2025 | Q3 FY2025 Jan – Mar 2025 | Q2 FY2025 Oct – Dec 2024 | Q1 FY2025 Jul – Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 105.8 | 13.2 | 29.2 | 54.6 | 8.8 | 6.5 | 14.8 | 17.1 | 88.9 |
| Gross profit | 26.6 | (3.7) | 8.4 | 18.0 | 3.9 | (20.1) | 3.7 | 9.5 | 24.8 |
| Operating profit | (62.4) | (36.7) | (4.9) | 10.3 | (31.1) | (612.5) | (7.3) | (9.5) | 134.5 |
| Profit after tax | (31.1) | (25.2) | (4.0) | 28.2 | (30.2) | (695.3) | (9.6) | (9.5) | 147.6 |
| Profit attributable to shareholders | (31.1) | (25.2) | (4.0) | 28.2 | (30.2) | (695.3) | (9.6) | (9.5) | 147.6 |
| EPS – basic (Rs) Rs | (0.22) | (0.17) | (0.03) | 0.25 | (0.27) | (9.14) | (0.08) | (0.08) | 1.35 |
| Dividend per share (Rs) Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total assets | 1,216.0 | 1,216.0 | 982.4 | 811.2 | 804.6 | 822.9 | 977.9 | 972.6 | 961.6 |
| Total equity | 985.5 | 985.5 | 828.0 | 631.9 | 603.7 | 633.9 | 895.9 | 904.3 | 922.6 |
| Total debt | 33.4 | 33.4 | 27.4 | 31.4 | 37.9 | 34.7 | 38.1 | 25.5 | 19.4 |
| Net cash from operating activities | 9.0 | 17.3 | (9.2) | 6.8 | (5.8) | 250.4 | (238.7) | (13.0) | (0.4) |
| Capital expenditure | (50.0) | (11.8) | (23.3) | (14.7) | (0.2) | (223.9) | (13.3) | (0.6) | — |
| Free cash flow (operating cash flow − capex) | (41.0) | 5.4 | (32.5) | (7.9) | (6.0) | 26.4 | (252.0) | (13.6) | — |
Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 16 Oct 2026.